Answers are grounded in this paper and cite their sources.
Plasmodium falciparum dihydrofolate reductase (DHFR) is the target of antimalarial drugs such as cycloguanil. However, mutations of DHFR, particularly the A16V and S108T variants, induce steric interactions that confer resistance to cycloguanil. It is crucial to find new therapeutics to combat cycloguanil-resistant strains of P. falciparum . We used in-silico methods to investigate possible drug candidates of A16V+S108T DHFR, a key cycloguanil-resistant double mutant. Using a large chemical library, we performed structure-based virtual screening to discover novel small molecule inhibitors of mutant DHFR. Molecular dynamics simulations show that the top-ranked compound from virtual screening, ligand 4, retains a stable binding pose. MM-GBSA calculations rank ligand 4 above cycloguanil and three other known DHFR inhibitors. Through these simulations, we identify a small molecule compound possessing more favorable binding free energies to DHFR than those of cycloguanil.
No takes yet. Share an insight, caveat, or question.
Baoerjin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: